Related Experiment Videos
SSRIs versus other antidepressants for depressive disorder
J R Geddes1, N Freemantle, J Mason
1Centre for Evidence-Based Health, University of Oxford, Warneford Hospital, Oxford, UK, OX3 7JX. john.geddes@psychiatry.ox.ac.uk
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Selective serotonin reuptake inhibitors (SSRIs) show no significant effectiveness difference compared to other antidepressants. Treatment choices should prioritize patient acceptability, toxicity, and cost for depression management.
Area of Science:
- Pharmacology
- Clinical Psychiatry
- Evidence-Based Medicine
Background:
- Depression is a prevalent mood disorder often treated with various antidepressant medications.
- Selective serotonin reuptuptake inhibitors (SSRIs) are a widely prescribed class of antidepressants.
- Comparative efficacy data between SSRIs and other antidepressant classes are crucial for clinical decision-making.
Purpose of the Study:
- To systematically evaluate and compare the relative efficacy of SSRIs against other antidepressant medications.
- To synthesize findings from randomized controlled trials (RCTs) assessing antidepressant effectiveness in depressive disorders.
Main Methods:
- A comprehensive literature search was conducted across multiple electronic databases and trial registers.
- Included were RCTs comparing SSRIs with alternative antidepressants for depression treatment.
- Efficacy was measured using standardized scales for depression severity, analyzed via standardized mean differences.
Main Results:
- Analysis included 98 trials with data from 5044 patients on SSRIs and 4510 on alternative antidepressants.
- The standardized effect size for SSRIs versus alternative antidepressants was 0.035 (95% CI -0.006 to 0.076), indicating no significant difference.
- Statistical analysis confirmed heterogeneity of treatment effects.
Conclusions:
- No clinically significant differences in effectiveness were found between SSRIs and tricyclic antidepressants.
- Treatment decisions should consider patient-specific factors like acceptability, toxicity, and cost.
- Further research may be needed to explore nuanced differences in patient populations.